-

Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Nasdaq has temporarily halted trading of the company's stock.

The Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee will meet today to review the premarket approval (PMA) application for ShieldTM, Guardant Health’s blood test to screen for colorectal cancer in average-risk adults.

The panel meeting is scheduled to begin at 9:30 a.m. ET.

FDA advisory committees provide independent expert advice and non-binding recommendations to the FDA on certain products to help the agency make sound decisions based on the available science.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Contacts

Investors:
Zarak Khurshid
investors@guardanthealth.com

Media:
Mike Weist
press@guardanthealth.com
+1 650-647-3643

Industry:

Guardant Health, Inc.

NASDAQ:GH
Release Versions
English

Contacts

Investors:
Zarak Khurshid
investors@guardanthealth.com

Media:
Mike Weist
press@guardanthealth.com
+1 650-647-3643

More News From Guardant Health, Inc.

Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present a total of 14 abstracts with its research collaborators from multiple studies demonstrating the value of its tissue-free liquid biopsy tests at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 9–12, 2025. Oral presentations will highlight results generated with Guardant Reveal, the company’s tissue-free test for detecting minimal residual disease (MRD...

Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the public launch of the Single Namespace Working Group (SNS), a 34-member, cross-industry consortium which has drafted the first open standard for exabyte-scale data interoperability. Managing exabyte-scale data across different storage providers is often disruptive, time-consuming, and ultimately costly due to progressively larger data sets needing faster solutions. SN...

Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the expansion of its Guardant Reveal® blood test to include late-stage therapy response monitoring for patients with solid tumors. Guardant Reveal tracks more than 20,000 epigenomic (methylation) signals to measure changes in circulating tumor DNA (ctDNA) levels in a patient’s blood to predict outcomes sooner than imaging without the need for a tissue sample. Building on...
Back to Newsroom